Literature DB >> 22297601

Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.

Tracy Madimabi Masebe1, Pascal Obong Bessong, Julius Nwobegahay, Roland Ndip Ndip, Debra Meyer.   

Abstract

Data on genetic polymorphisms associated with response to anti-HIV drugs has accumulated over the years. Information on how polymorphisms influence drug metabolism and transport to target sites is important in guiding dosage or selection of appropriate alternative therapies. This study determined the frequency of MDR1 C3435T and CYP2B6 G516T polymorphisms associated with the transport and metabolism of efavirenz and nevirapine, in a population of South African HIV infected patients. In addition, association of polymorphisms with immunologic and virologic factors was investigated. A 207bp of MDR1 exon 26 and a 161bp of CYP2B6 exon 4 were obtained from patients by polymerase chain reaction. Analysis of population-based sequences of MDR1 revealed a frequency of 89% and 11% of C and T alleles respectively (n=197; X<formula>^{2} =</formula> 0.974; p=0.324). Restriction fragment length polymorphism (RFLP) analysis of the CYP2B6 gene revealed a prevalence of 9.5% of GG, 78.4% of GT and 12.1% of TT genotype (n= 199; X<formula>^{2} =</formula> 65.204; p=0.00). There was no significant difference between immune recovery and decline in viral load (n=53), with genotype after repeated calculations of analysis of variance (ANOVA).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297601      PMCID: PMC3826384          DOI: 10.3233/DMA-2012-0859

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  7 in total

1.  CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Authors:  Carolyn Bolton Moore; Edmund V Capparelli; Pearl Samson; Mutsa Bwakura-Dangarembizi; Patrick Jean-Philippe; Carol Worrell; Barbara Heckman; Lynette Purdue; Stephen A Spector; Alex Benns; William Borkowsky; Amy Loftis; Elizabeth Hawkins; Carole Wallis; Ellen G Chadwick
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

2.  Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.

Authors:  Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Audrey L French; Marla J Keller; Michael H Augenbraun; Stephen J Gange; Chenglong Liu; Wendy J Mack; Monica Gandhi
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 3.  Genetic Diversity in Drug Transporters: Impact in African Populations.

Authors:  Iris Rajman; Laura Knapp; Imad Hanna
Journal:  Clin Transl Sci       Date:  2020-03-31       Impact factor: 4.689

4.  Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes.

Authors:  Sibongile Tshabalala; Ananyo Choudhury; Natasha Beeton-Kempen; Neil Martinson; Michèle Ramsay; Dalu Mancama
Journal:  Pharmacogenet Genomics       Date:  2019-09       Impact factor: 2.089

Review 5.  Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview.

Authors:  Pascal O Bessong; Nontokozo D Matume; Denis M Tebit
Journal:  AIDS Res Ther       Date:  2021-01-06       Impact factor: 2.250

6.  Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.

Authors:  Tracy Masebe; Pascal Obong Bessong; Roland Ndip Ndip; Debra Meyer
Journal:  Int J Mol Sci       Date:  2014-06-26       Impact factor: 5.923

7.  Distribution of CYP2B6 516G/T pharmacogenetically important polymorphism in the Ukrainian population.

Authors:  Olga Filiptsova; Marina Kobets; Julia Kobets; Olga Naboka; Olga Koiro; Alexandr Ochkur; Larisa Galiy
Journal:  Saudi Pharm J       Date:  2018-02-15       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.